Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 670 across all filing types
Latest filing 2020-09-09 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
首次公开发行股票网上发行申购情况及中签率公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the subscription situation and lottery results for the online issuance of shares in the company's initial public offering (IPO). It details the number of shares issued, subscription rates, the application process, and the lottery draw for allotment. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is a formal announcement related to the capital issuance process, specifically the subscription and allotment results of the IPO shares. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is under 5,000 characters and is a detailed announcement, not just a brief note about a report publication, so it is not RPA or RNS.
2020-09-09 Chinese
首次公开发行股票投资风险特别公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the initial public offering (IPO) of 奥锐特药业股份有限公司, including information about the number of shares to be issued, pricing, subscription process, risk factors, and regulatory approvals. It discusses the issuance of new shares, pricing, subscription timelines, and investor instructions. The document is not a financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is clearly an update on capital raising activity through a public offering of shares. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2020-09-07 Chinese
首次公开发行股票招股说明书摘要
Capital/Financing Update Classification · 95% confidence The document is titled as a "首次公开发行股票招股说明书摘要" which translates to "Summary of the Prospectus for Initial Public Offering (IPO)". It contains detailed information about the company's stock issuance, shareholder commitments, lock-up periods, dividend policies, stock price stabilization plans, risk factors, and legal commitments related to the IPO process. The document is lengthy (15,000 characters) and contains substantive content related to the IPO offering, shareholder commitments, and regulatory compliance. This type of document is a prospectus or offering document related to capital raising through an IPO, which falls under the category of Capital/Financing Update (CAP) as it deals with the company's fundraising and issuance of new shares to the public. It is not an annual report, earnings release, or other financial report. It is also not a simple announcement or regulatory filing but a detailed offering document. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-09-07 Chinese
首次公开发行股票招股说明书
Capital/Financing Update Classification · 95% confidence The document is titled "首次公开发行股票招股说明书" which translates to "Initial Public Offering (IPO) Prospectus" or "Stock Issuance Prospectus." It contains detailed information about the company's stock issuance, share lock-up commitments by shareholders and executives, dividend policies, and stock price stabilization plans post-listing. The document is lengthy (15,000 characters) and contains substantive content related to the company's capital raising and share issuance. This is not an announcement or a brief summary but a full prospectus document related to the company's initial public offering. According to the filing definitions, this type of document fits best under "Capital/Financing Update (CAP)" as it relates to fundraising and capital structure changes through an IPO. It is not an Annual Report, Earnings Release, or any other category. Therefore, the correct classification is CAP with high confidence.
2020-09-07 Chinese
首次公开发行股票发行公告
Capital/Financing Update Classification · 100% confidence The document is a detailed announcement regarding the initial public offering (IPO) of 奥锐特药业股份有限公司 (Aoruite Pharmaceutical Co., Ltd.). It includes information about the issuance of new shares, pricing, subscription procedures, allocation mechanisms, underwriting, and regulatory approvals. The text references regulatory rules and guidelines related to securities issuance and underwriting, specifies the number of shares to be issued, the pricing process, subscription dates, and the roles of the sponsor and underwriter. It also discusses the allotment results announcement and payment instructions for investors. This document is clearly an official announcement related to the issuance of new shares in a public offering, which fits the category of Capital/Financing Update (CAP). It is not a full financial report, earnings release, or regulatory filing unrelated to financing. The length and detail confirm it is not a mere announcement of a report publication (RPA) but the actual issuance announcement itself.
2020-09-07 Chinese
首次公开发行股票网上路演公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the online roadshow for the initial public offering (IPO) of 奥锐特药业股份有限公司. It details the stock issuance plan, the approval by the China Securities Regulatory Commission, the schedule and website for the online roadshow, and the participation of the company's board and management. It also references the prospectus summary published earlier and where the full prospectus can be found. The document is short (852 characters) and serves as an announcement to investors about the IPO roadshow event rather than the IPO prospectus or detailed financial report itself. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities such as IPOs.
2020-09-06 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.